Werbung
Werbung

ATRA

ATRA logo

Atara Biotherapeutics, Inc

13.79
USD
Gesponsert
-3.65
-20.94%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

13.69

-0.10
-0.71%

ATRA Ergebnisberichte

Positives Überraschungsverhältnis

ATRA übertreffen die 19 der letzten 40Schätzungen.

48%

Nächster Bericht

Datum des nächsten Berichts
05. März 2026
Estimate for Q4 25 (Revenue/ EPS)
$2.72M
/
-$0.44
Implizierte Änderung von Q3 25 (Revenue/ EPS)
-21.09%
/
+37.50%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
-91.68%
/
-63.03%

Atara Biotherapeutics, Inc earnings per share and revenue

On 12. Nov. 2025, ATRA reported earnings of -0.32 USD per share (EPS) for Q3 25, beating the estimate of -0.87 USD, resulting in a 63.52% surprise. Revenue reached 3.45 million, compared to an expected 1.43 million, with a 142.21% difference. The market reacted with a -0.72% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -0.44 USD, with revenue projected to reach 2.72 million USD, implying an increase of 37.50% EPS, and decrease of -21.09% in Revenue from the last quarter.
FAQ
For Q3 2025, Atara Biotherapeutics, Inc reported EPS of -$0.32, beating estimates by 63.52%, and revenue of $3.45M, 142.21% above expectations.
The stock price moved down -0.72%, changed from $12.56 before the earnings release to $12.47 the day after.
The next earning report is scheduled for 05. März 2026.
Based on 6 analysts, Atara Biotherapeutics, Inc is expected to report EPS of -$0.44 and revenue of $2.72M for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung